Mineralys Therapeutics, Inc.
MLYSDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Upcoming FDA decisions
lorundrostat Dose 1
Hypertension
Lorundrostat
Obstructive Sleep Apnea
MLS-101 (Part I)
Hypertension, Renal
lorundrostat Dose 2
Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lorundrostat Dose 1 | Phase 3 | Hypertension | - | - |
Lorundrostat | Phase 3 | Obstructive Sleep Apnea | - | - |
MLS-101 (Part I) | Phase 2 | Hypertension, Renal | - | - |
lorundrostat Dose 2 | Phase 2 | Hypertension | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mineralys Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Mineralys Therapeutics, Inc.'s (MLYS) pipeline across Phase 3, Phase 2. Its lead program is lorundrostat Dose 1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mineralys Therapeutics, Inc.'s next FDA catalyst?→
Mineralys Therapeutics, Inc.'s (MLYS) next tracked catalyst is a Earnings expected November 9, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MLYS biotech catalysts?→
Add MLYS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mineralys Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.